The molecular diagnostics market, in which Cepheid (CPHD) is a prominent player, is expected to grow rapidly at a 42% CAGR through 2017. Currently CPHD is trading at a multi-year high due to the immense industry growth prospects.
CPHD has a broad range of tests that runs on its GeneXpert systems across infectious diseases, hospital acquired infections ("HAI"), women's health, genetics and oncology. I believe that two recent developments can drive the company's stock ~25% higher from the current level around $47. This article will focus on these developments.
Growth Opportunities from TB Detection
A few months ago the FDA approved Cepheid to market its Xpert MTB/RIF assay in the U.S. It's...
Only subscribers can access this article, which is part of the PRO research library covering 3,555 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: